Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

Frank A Bucci Jr,1 Ruth E Evans,1 Loretta M Amico,1 Timothy W Morris,2 Angel T Fluet,1 Christine M Sanfilippo,3 Heleen H DeCory,3 Timothy L Comstock3 1Bucci Laser Vision Institute, Wilkes-Barre, PA, USA; 2Microbiology and Sterilization Sciences, Bausch and Lomb, Rochester, NY, USA; 3Medical Affairs...

Full description

Bibliographic Details
Main Authors:	Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-05-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/antibacterial-efficacy-of-prophylactic-besifloxacin-06-and-moxifloxaci-peer-reviewed-article-OPTH

Similar Items

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
by: Silverstein BE, et al.
Published: (2012-11-01)

Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
by: Comstock TL, et al.
Published: (2014-04-01)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
by: Morris TW, et al.
Published: (2011-09-01)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
by: Blondeau JM, et al.
Published: (2021-11-01)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
by: Haas W, et al.
Published: (2011-09-01)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
by: Heleen H DeCory, et al.
Published: (2020-01-01)

Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery
by: Bucci Jr FA, et al.
Published: (2016-05-01)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
by: Joseph Blondeau, et al.
Published: (2021-05-01)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
by: Haas W, et al.
Published: (2013-05-01)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
by: Nielsen SA, et al.
Published: (2013-01-01)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
by: Fong R, et al.
Published: (2019-08-01)

Safety of prophylactic intracameral moxifloxacin ophthalmic solution after cataract surgery in patients with penetrating keratoplasty
by: Osman Sevki Arslan, et al.
Published: (2014-10-01)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
by: Coffey MJ, et al.
Published: (2013-02-01)

Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation
by: José Izo Santana da Silva de Jesus, et al.
Published: (2022-10-01)

Spectral Analysis and Structural Elucidation of Besifloxacin Hydrochloride
by: ZHANG Ming-guang, et al.
Published: (2018-09-01)

Application of intracameral moxifloxacin to prevent endophthalmitis in cataract surgery
by: Servet Cetinkaya, et al.
Published: (2015-10-01)

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach
by: Turki Al Hagbani, et al.
Published: (2023-07-01)

Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes
by: G.C.M. Silva, et al.

Probing the current-phase relation in Josephson point-contact junctions between $$\hbox {Pb}_{0.6}$$ Pb 0.6 In $$_{0.4}$$ 0.4 and $$\hbox {Ba}_{0.6}$$ Ba 0.6 K $$_{0.4}$$ 0.4 (FeAs) $$_2$$ 2 superconductors
by: Valeriy A. Stepanov, et al.
Published: (2021-12-01)

Dielectric characterization of Ba0.6La0.4Sn0.6Mn0.4O3 ceramic
by: Primus, Walter Charles, et al.
Published: (2010)

Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis
by: Jun-Jie Wang, et al.
Published: (2019-12-01)

Endophthalmitis following cataract surgery and intracameral antibiotic: Moxifloxacin resistant Staphylococcus epidermidis
by: Victoria S. Chang, et al.
Published: (2019-03-01)

Intravitreal moxifloxacin injections in acute post-cataract surgery endophthalmitis: Efficacy and safety
by: Abhishek Agarwal, et al.
Published: (2021-01-01)

Anaphylactoid reaction following topical moxifloxacin eye drops after cataract surgery
by: B Koshal Ram, et al.
Published: (2021-01-01)

A Case Report of Severe Corneal Toxicity following 0.5% Topical Moxifloxacin Use
by: A.P. Vignesh, et al.
Published: (2015-02-01)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
by: S. Khimdas, et al.
Published: (2011-01-01)

Optical and functional properties of hydrothermally synthesized tetragonal Ba0.4Cu0.6−xLaxTiO3 (x = 0.2–0.6) nanoparticles
by: M Prakash, et al.
Published: (2020-01-01)

Properties of Mn0.4Zn0.6Fe2O4 and Mn0.6Zn0.4Fe2O4 as Nanocatalyst for Ammonia Production
by: Puspitasari Poppy, et al.
Published: (2017-01-01)

Study of shear for steel fibre reinforced concrete beam with ratio 0.2%, 0.4%, 0.6%, 0.8% and 1.0%
by: Ummi Izni, Mohamad Tarmizi
Published: (2010)

The Effect of Annealing on the Microstructure and Properties of Ultralow-Temperature Rolled Mg–2Y–0.6Nd–0.6Zr Alloy
by: Hongmin Yu, et al.
Published: (2021-02-01)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
by: Timothy L Comstock, et al.
Published: (2011-02-01)

Preparation of Zn0.6Cd0.4o nanorods and its characterization
by: Mohamad, Souad A., et al.
Published: (2013)

Dielectric properties of La0.67sr0.33Mnl-xTix03 with x = 0.4 and 0.6.
by: Zalita , Z., et al.
Published: (2011)

Optimization of La0.6Sr0.4Co0.2Fe0.8O3-α - Ba(Ce0.6Zr0.4)0.9Y0.1O3-δ cathode composition for proton ceramic fuel cell application
by: Ismail Ismariza, et al.
Published: (2022-12-01)

Effect of ECAP on the Microstructure and Mechanical Properties of a Rolled Mg-2Y-0.6Nd-0.6Zr Magnesium Alloy
by: Xiaofang Shi, et al.
Published: (2019-11-01)

Alternating current magnetotransport in Sm0.1La0.6Sr0.3MnO3
by: M. Aparnadevi, et al.
Published: (2013-01-01)

Structural, Electrical and Optical Studies of ZnxCu1-xS (x = 0.8, 0.6, 0.4 and 0.2) Nanoparticles
by: Moly M. Rose, et al.
Published: (2023-03-01)

Structural effect on Magneto-electric properties in (1-x) BiFe0.9La0.1O3 + xNi0.6Zn0.4Fe1.94V0.06O4 composites
by: M.R. Hassan, et al.
Published: (2021-07-01)

Synthesis and characterisation of Sr1.2Nd0.8Mn0.6Rh0.4O4
by: Gallon, D, et al.
Published: (2003)

Microstructure of Al-5Cu-1Li-0.6Mg-0.5Ag-0.5Mn Alloys
by: Wenzheng Chen, et al.
Published: (2020-12-01)